| Multiple Myeloma

Ninlaro vs Kyprolis

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Ninlaro vs Kyprolis with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKyprolis has a higher rate of injection site reactions vs Ninlaro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Kyprolis but not Ninlaro, including UnitedHealthcare

Category

Ninlaro

Kyprolis

At A Glance

RouteOral

FrequencyOnce weekly (Days 1, 8, 15 of 28-day cycle)

ClassProteasome inhibitor

RouteIV infusion

FrequencyOnce or twice weekly

ClassProteasome inhibitor

Indications

Multiple Myeloma

Multiple Myeloma

Dosing

Multiple Myeloma 4 mg orally once weekly on Days 1, 8, and 15 of a 28-day cycle in combination with lenalidomide 25 mg daily (Days 1-21) and dexamethasone 40 mg (Days 1, 8, 15, 22); reduce starting dose to 3 mg for moderate or severe hepatic impairment, severe renal impairment (CrCl <30 mL/min), or ESRD requiring dialysis.

Multiple Myeloma 20/70 mg/m2 IV once weekly as a 30-minute infusion on Days 1, 8, and 15 of each 28-day cycle (in combination with dexamethasone, daratumumab plus dexamethasone, or daratumumab and hyaluronidase-fihj plus dexamethasone); start at 20 mg/m2 on Cycle 1, Day 1, escalate to 70 mg/m2 on Cycle 1, Day 8 if tolerated.

Multiple Myeloma 20/56 mg/m2 IV twice weekly as a 30-minute infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (as monotherapy or in combination with dexamethasone, daratumumab plus dexamethasone, daratumumab and hyaluronidase-fihj plus dexamethasone, or isatuximab plus dexamethasone); start at 20 mg/m2 on Cycle 1, Days 1 and 2, escalate to 56 mg/m2 on Cycle 1, Day 8 if tolerated.

Multiple Myeloma 20/27 mg/m2 IV twice weekly as a 10-minute infusion on Days 1, 2, 8, 9, 15, and 16 (Cycles 1-12) or Days 1, 2, 15, and 16 (Cycle 13+) of each 28-day cycle (as monotherapy or in combination with lenalidomide and dexamethasone); start at 20 mg/m2 on Cycle 1, Days 1 and 2, escalate to 27 mg/m2 on Cycle 1, Day 8 if tolerated.

Contraindications

—

Drug Interactions

1162View drug interactions

1089View drug interactions

Adverse Reactions

Most common (>=20%) Thrombocytopenia, neutropenia, diarrhea, constipation, peripheral neuropathy, nausea, peripheral edema, rash, vomiting, bronchitis

Serious Diarrhea, thrombocytopenia, bronchitis

Postmarketing Angioedema, toxic epidermal necrolysis

Most common (>=20%) Anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, insomnia

Serious Cardiac toxicities, acute renal failure, tumor lysis syndrome, pulmonary toxicity, pulmonary hypertension, venous thrombosis, infusion-related reactions, hemorrhage, hepatic toxicity and failure, thrombotic microangiopathy, posterior reversible encephalopathy syndrome, progressive multifocal leukoencephalopathy

Postmarketing Hemolytic uremic syndrome, hepatitis B virus reactivation, gastrointestinal perforation, pericarditis, cytomegalovirus infection

Pharmacology

Ixazomib is a reversible proteasome inhibitor that preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome, inducing apoptosis in multiple myeloma cell lines and demonstrating synergistic cytotoxic effects in combination with lenalidomide.

Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome within the 26S proteasome, producing antiproliferative and proapoptotic effects in hematologic and solid tumor cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Ninlaro